Claiming that the domestic market undervalues pharma innovation, Merck has decided to pull the plug on all of its R&D efforts in the U.K.
Merck Abandons $1.3B R&D Center in London, Boots 125 Employees Read More »
La empresa moderna pide foco. Pide velocidad. Pide sistemas que no fallen. Soft2Bet responde con una plataforma firme y dúctil. La base es clara. Tecnología que encaja. Operativa que fluye. Resultados que se miden. Aquí verás cómo su propuesta eleva el rendimiento …
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. This webinar will show leaders how strategic insights and targeted outreach can turn awareness into high-converting leads. Watch now.
2026 will mark the fourth consecutive year of substantial health benefit cost growth, signaling “mounting pressure on employers’ healthcare budgets.”
Health benefit cost increases expected to hit 15-year high, Mercer warns Read More »
The autoimmune and inflammatory disease–focused company canceled plans to go public earlier this year as the IPO window slammed shut.
Odyssey Rebounds Off Failed IPO With $213M Series D Read More »
The board of directors called for Derick Apt to resign, amid allegations he improperly accepted a “series of high value” gifts.
Pacs Group CFO resigns amid allegations of improper conduct Read More »
The nonpartisan scorekeeper’s new report reinforces longstanding concerns about the 340B drug discount program, including that it incentivizes behaviors that increase health costs for federal and private payers.
340B incentivizes hospital-clinic M&A, drives higher health spending: CBO Read More »
BTIG analysts estimate that Elutia’s Elupro and Medtronic’s TYRX are competing for a $600 million opportunity in the U.S. cardiac rhythm management sector.
Boston Scientific inks $88M Elutia deal to challenge Medtronic Read More »
The prosecutor’s office opened an investigation in June, with charges including aggravated fraud and failure to report incidents that pose serious health risks.
The high court granted an expedited review of an appellate court finding that the president’s sweeping tariffs were illegal.
Supreme Court to hear Trump’s tariff legality case in November Read More »
